Glycopyrrolate by Rising Pharma Holdings, Inc. / Suven Pharmaceuticals Limited GLYCOPYRROLATE tablet

Glycopyrrolate by

Drug Labeling and Warnings

Glycopyrrolate by is a Prescription medication manufactured, distributed, or labeled by Rising Pharma Holdings, Inc., Suven Pharmaceuticals Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS & USAGE

    Glycopyrrolate are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.

    Limitations of Use
    Glycopyrrolate are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.

  • 2 DOSAGE & ADMINISTRATION

    2.1 Important Dosing Information

     Glycopyrrolate is not recommended for patients in whom a lower dosage strength of oral glycopyrrolate (e.g., glycopyrrolate or another 1 mg tablet strength) is appropriate for initial or maintenance treatment because the dosage strength of glycopyrrolate may exceed the recommended initial and maintenance dosage of oral glycopyrrolate tablets.

    2.2 Recommended Dosage

     The recommended initial dosage of glycopyrrolate for adults is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate.

     The recommended dosage of glycopyrrolate for adults is 2 mg two or three times daily at equally spaced intervals.

     The maximum recommended daily dosage of glycopyrrolate is 8 mg.

     Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate or another 1 mg oral tablet of glycopyrrolate.


  • 3 DOSAGE FORMS & STRENGTHS

    Tablets:
     1 mg, white, round, flat-faced, beveled-edge tablet, debossed “CS” and “007” on one side and functionally scored on the other side.
     2 mg, white, round, flat-faced, beveled-edge tablet, debossed “CS” score “008” on one side and plain on the other side.


  • 4 CONTRAINDICATIONS

    Glycopyrrolate are contraindicated in:

     Patients at risk for anticholinergic toxicity due to an underlying medical condition, including:

          o Glaucoma [see Warnings and Precautions (5.1)]
          o Obstructive uropathies, including prostatic hypertrophy
          o Mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [see Warnings and Precautions (5.2)]
          o Gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony) [see  Warnings and Precautions (5.3)]
          o Bleeding gastrointestinal ulcer
          o Active inflammatory or infectious colitis which can lead to toxic megacolon
          o History of or current toxic megacolon
          o Myasthenia gravis

     Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate [see Adverse Reactions (6) and Description (11)].


  • 5 WARNINGS AND PRECAUTIONS

    5.1 Precipitation of Acute Glaucoma

    Glycopyrrolate may cause increased intraocular pressure in patients with glaucoma and reduce the effects of antiglaucoma agents. Instruct patients to discontinue glycopyrrolate and promptly seek medical care if they experience symptoms of acute angle-closure glaucoma (pain and reddening of the eyes accompanied by dilated pupils) [see Contraindications (4)].

    5.2 Partial or Complete Mechanical Intestinal Obstruction

    Glycopyrrolate may worsen intestinal mechanical obstruction, and diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. If partial or complete intestinal obstruction is suspected, discontinue the use of glycopyrrolate and evaluate for potential intestinal obstruction [see Contraindications (4)].

    5.3 Gastrointestinal Adverse Reactions Due to Decreased Gastrointestinal Motility

    Glycopyrrolate reduces gastrointestinal motility and may result in delayed gastric emptying, constipation, and intestinal pseudo-obstruction and may precipitate or aggravate paralytic ileus and toxic megacolon [see Contraindications (4)]. The risk of gastrointestinal adverse reactions is further increased with the use of other anticholinergics and other medications that decrease gastrointestinal peristalsis.

    Monitor patients for symptoms of decreased gastrointestinal motility. Concomitant use of glycopyrrolate and other anticholinergics or other medications that decrease GI peristalsis is not recommended [see Drug Interactions (7.2)].


    5.4 Cognitive and Visual Adverse Reactions

    Glycopyrrolate may produce drowsiness and blurred vision and impair the mental and/or physical abilities required for the performance of hazardous tasks such as driving a motor vehicle, operating machinery, or performing other hazardous work [see Adverse Reactions (6)]. Concomitant use of other drugs that have anticholinergic properties may increase these effects [see Drug Interactions (7.1)].

    Inform patients not to operate motor vehicles or other dangerous machinery or perform other hazardous tasks until they are reasonably certain that glycopyrrolate does not affect them adversely.
    Discontinue glycopyrrolate if signs or symptoms of cognitive or visual impairment develop.


    5.5 Heat Prostration at High Environmental Temperatures

    In the presence of a high environmental temperature, heat prostration resulting in fever and heatstroke can occur with the use of glycopyrrolate due to decreased sweating, particularly in geriatric patients [see Adverse Reactions (6)]. Advise patients to avoid exposure to hot or very warm environmental temperatures when taking glycopyrrolate. Glycopyrrolate are not recommended in geriatric patients [see Warnings and Precautions (5.7)].

    5.6 Other Conditions Exacerbated by Anticholinergic Adverse Reactions

    Glycopyrrolate are not recommended in patients with other conditions exacerbated by anticholinergic adverse reactions (e.g., autonomic neuropathy, hyperthyroidism, cardiac disease, and hiatal hernia associated with reflux esophagitis) and in patients taking other anticholinergic medications [see Drug Interactions (7.1)].

    5.7 Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients

    Geriatric patients 65 years of age and older are at increased risk of anticholinergic adverse reactions that may lead to complications of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures. Glycopyrrolate are not recommended in geriatric patients and may be contraindicated in some geriatric patients with underlying medical conditions [see Contraindications (4),Warnings and Precautions (5.2, 5.5), Adverse Reactions (6) and Use in Specific Populations (8.5)].

  • 6 ADVERSE REACTIONS

    The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:

     Precipitation of Acute Glaucoma [see Warnings and Precautions (5.1)]

     Partial or Complete Mechanical Intestinal Obstruction [see Warnings and Precautions (5.2)]

     Gastrointestinal Adverse Reactions due to Decreased Gastrointestinal Motility [see Warnings and Precautions (5.3)]

     Cognitive and Visual Adverse Reactions [see Warnings and Precautions (5.4)]

     Heat Prostration at High Environmental Temperatures [see Warnings and Precautions (5.5)]

     Other Conditions Exacerbated by Anticholinergic Adverse Reactions [see Warnings and Precautions (5.6)]

     Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients [see Warnings and Precautions (5.7)]

    The following adverse reactions associated with the use of glycopyrrolate, or other anticholinergic drugs, were identified in clinical studies or postmarketing reports. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Cardiac Disorders: chest, pain, hypertension, tachycardia

    Endocrine Disorders: decreased sweating

    Eye Disorders: blurred vision, cycloplegia, dilatation of the pupil, increased ocular tension

    Gastrointestinal Disorders: bloated feeling, constipation, dry mouth, dysgeusia, nausea, vomiting

    Immune System Disorders: anaphylaxis [see Contraindications (4)]

    Nervous System Disorders: agitation, dizziness, drowsiness, headache, insomnia, mental confusion, nervousness, weakness

    Respiratory Disorders: respiratory depression, throat irritation

    Renal and Urinary Disorders: urinary hesitancy, urinary retention

    Reproductive System and Breast Disorders: impotence, suppression of lactation

    Vascular Disorders: flushing


  • 7 DRUG INTERACTIONS

    7.1 Other Anticholinergic Drugs

    There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. Co-administration of antipsychotics with glycopyrrolate may lead to worsening of tardive dyskinesia. Glycopyrrolate are not recommended in patients taking other anticholinergic drugs [see Warnings and Precautions (5.3, 5.4, 5.6)].

    7.2 Drugs with Altered Absorption due to Decreased Gastrointestinal Motility and Increased Transit Time

    Decreased gastrointestinal motility by glycopyrrolate may impact absorption of other drugs leading to increased or decreased drug exposure. Glycopyrrolate are not recommended in patients taking other drugs that are affected by altered gastrointestinal motility [see Warnings and Precautions (5.3)].

    7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride

    Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time, leading to prolonged contact with the gastrointestinal mucosa. Glycopyrrolate are not recommended in patients taking solid oral dosage forms of potassium chloride.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    Over decades of use, there is an absence of published data on orally administered glycopyrrolate in pregnant women, including an absence of any reports of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal studies, at non-maternally toxic doses of oral glycopyrrolate, there were no adverse developmental effects in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed (see Data).

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

     Data 
    Animal Data

    At non-maternally toxic doses of oral glycopyrrolate, there were no effects on embryo-fetal development or toxicity in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed.

    In a published reproductive and developmental study, male and female rats were administered glycopyrrolate in the diet at 0 mg/kg/day, 32.5 mg/kg/day, 63 mg/kg/day, and 130 mg/kg/day for 3 weeks to 5 weeks and through up to three consecutive litters. There was no indication of abnormalities in the pups of treated dams. There was a decreased rate of conception and in survival rate at weaning for all treated animals in a dose-related manner. Diminished rates of conception may be due to diminished seminal secretion [see Nonclinical Toxicology (13.1)].


    8.2 Lactation

    Risk Summary
    There are no data on the presence of glycopyrrolate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. As with other anticholinergic drugs, glycopyrrolate may cause suppression of lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for glycopyrrolate and any potential adverse effects on the breastfed infant from glycopyrrolate.


    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    Geriatric patients 65 years of age and older may be more sensitive to the anticholinergic adverse reactions of glycopyrrolate leading to complications of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures; therefore, glycopyrrolate are not recommended in geriatric patients and may be contraindicated in some geriatric patients with underlying medical conditions [see Contraindications (4) and Warnings and Precautions (5)].

    8.6 Renal Impairment

    Glycopyrrolate is substantially excreted by the kidney [see Clinical Pharmacology (12.3)].

    Monitor patients with renal impairment for anticholinergic adverse reactions [see Adverse Reactions (6)]. If anticholinergic adverse reactions occur, discontinue glycopyrrolate.

  • 10 OVERDOSAGE

    Signs and symptoms of glycopyrrolate overdosage are related to excessive anti-muscarinic anticholinergic activity and are generally peripheral (e.g., flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation, and light sensitivity due to mydriasis), but central nervous system toxicity (agitation, seizures, hyperthermia) may also occur.

    If over-exposure occurs, call the Poison Control Center at 1-800-222-1222 for current information on the management of glycopyrrolate poisoning and overdosage.

    Management of glycopyrrolate overdosage is based upon presenting signs and symptoms, including close observation for severe or life-threatening complications which may require respiratory and cardiovascular monitoring and support. Consider administration of activated charcoal and/or use of a reversible anticholinesterase as appropriate or recommended by Poison Control.


  • 11 DESCRIPTION

    Glycopyrrolate Tablets, USP contain synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentyl hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. The molecular formula for glycopyrrolate is C19H28BrNO3, the molecular weight is 398.3 g/mol, and the structural formula is:



    glycopyrrolate-struct

    Each glycopyrrolate tablet contains glycopyrrolate, USP 1 mg, as the active ingredient. Each glycopyrrolate tablet contains glycopyrrolate, USP 2 mg, as the active ingredient. The inactive ingredients are dibasic calcium phosphate, lactose monohydrate, magnesium stearate, povidone, and sodium starch glycolate.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Glycopyrrolate, an anticholinergic (antimuscarinic) agent, inhibits the action of acetylcholine on parietal cells in the stomach and decreases the volume and acidity of gastric secretions.

    12.2 Pharmacodynamics

    No formal pharmacodynamic studies have been conducted with glycopyrrolate.

    12.3 Pharmacokinetics

    Patients with Renal Impairment

    In the published literature, glycopyrrolate 4 mcg/kg was administered intravenously (glycopyrrolate are not recommended for intravenous use) in uremic patients undergoing renal transplantation surgery. The mean    AUC (10.6 mcg·h/L) and 24-hour urinary excretion (7%) for glycopyrrolate were significantly different from normal healthy adult subjects undergoing general surgery (3.7 mcg·h/L, and 65%, respectively) [see Use in Specific Populations (8.6)].


  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility

    Reproduction studies in rats resulted in diminished rates of conception in a dose-related manner. Studies in dogs suggest that diminished rates of conception may be due to diminished seminal secretion, which is evident at high doses of glycopyrrolate.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Glycopyrrolate Tablets USP, 1 mg are white, round, flat-faced, beveled-edge tablet, debossed “CS” and “007” on one side and functionally scored on the other side. Available as

     Bottles of 30  NDC 16571-743-03
     Bottles of 90  NDC: 16571-743-09

    Glycopyrrolate Tablets USP, 2 mg are white, round, flat-faced, beveled-edge tablet, debossed “CS” score “008” on one side and plain on the other side. Available as

     Bottles of 30  NDC: 16571-744-03
     Bottles of 90  NDC 16571-744-09

    Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.

    Dispense in tight container.


  • 17 PATIENT COUNSELING INFORMATION

    Precipitation of Acute Glaucoma
    Advise patients to discontinue glycopyrrolate and promptly seek medical care if they experience symptoms of acute angle-closure glaucoma (pain and reddening of the eyes accompanied by dilated pupils) [see Warnings and Precautions (5.1)].

    Partial or Complete Mechanical Intestinal Obstruction
    Advise patients to contact their healthcare provider if diarrhea occurs, especially in patients with ileostomy or colostomy [see Warnings and Precautions (5.2)].

    Gastrointestinal Adverse Reactions Due to Decreased Gastrointestinal Motility
    Inform patients that glycopyrrolate may cause adverse reactions related to decreased gastrointestinal motility and report to their healthcare provider if they experience symptoms such as vomiting, early satiety, abdominal distention, and constipation [see Warnings and Precautions (5.3)].

    Cognitive and Visual Adverse Reactions
    Inform patients that glycopyrrolate may cause cognitive or visual impairment and not operate motor vehicles or other dangerous machinery or perform other hazardous tasks until they are reasonably certain that glycopyrrolate do not affect them adversely. Advise patients to discontinue glycopyrrolate immediately and contact their healthcare provider if symptoms develop (e.g., drowsiness or blurred vision) [see Warnings and Precautions (5.4)].

    Heat Prostration at High Environmental Temperatures

    Inform patients that glycopyrrolate can reduce sweating, leading to the possibility of heat exhaustion or heat stroke. Advise patients to avoid exposure to hot or very warm environmental temperatures [see Warnings and Precautions (5.5)].

    Distributed by:
    Rising Pharma Holdings, Inc.
    East Brunswick, NJ 08816

    Manufactured by:
    Suven Pharmaceuticals Limited,
    Telangana, India

    M.L.No.: 24/MD/AP/2009/F/CC

    Revised: 10/2022

    PIA74409-02


  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Rising®         NDC: 16571-743-09

    Glycopyrrolate
    Tablets, USP
    WHITE DYE-FREE
    1 mg
    90 Tablets     Rx only

    gylcopyrrolate-1mg

    Rising®         NDC: 16571-744-09

    Glycopyrrolate
    Tablets, USP
    WHITE DYE-FREE
    2 mg
    90 Tablets     Rx only

    glycopyrrolate-2mg

  • INGREDIENTS AND APPEARANCE
    GLYCOPYRROLATE 
    glycopyrrolate tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 16571-743
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GLYCOPYRROLATE (UNII: V92SO9WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D) GLYCOPYRROLATE1 mg
    Inactive Ingredients
    Ingredient NameStrength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITEScore2 pieces
    ShapeROUNDSize8mm
    FlavorImprint Code CS;007
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 16571-743-0330 in 1 CONTAINER; Type 0: Not a Combination Product10/06/2020
    2NDC: 16571-743-0990 in 1 CONTAINER; Type 0: Not a Combination Product10/06/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDA AUTHORIZED GENERICNDA01282710/06/2020
    GLYCOPYRROLATE 
    glycopyrrolate tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 16571-744
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GLYCOPYRROLATE (UNII: V92SO9WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D) GLYCOPYRROLATE2 mg
    Inactive Ingredients
    Ingredient NameStrength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITEScore2 pieces
    ShapeROUNDSize10mm
    FlavorImprint Code CS;008
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 16571-744-0330 in 1 CONTAINER; Type 0: Not a Combination Product10/06/2020
    2NDC: 16571-744-0990 in 1 CONTAINER; Type 0: Not a Combination Product10/06/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDA AUTHORIZED GENERICNDA01282710/06/2020
    Labeler - Rising Pharma Holdings, Inc. (835513529)
    Establishment
    NameAddressID/FEIBusiness Operations
    Suven Pharmaceuticals Limited677604288ANALYSIS(16571-743, 16571-744) , API MANUFACTURE(16571-743) , LABEL(16571-743, 16571-744) , MANUFACTURE(16571-743, 16571-744) , PACK(16571-743, 16571-744)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.